| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.79 [0.68, 0.92] | | < 1 | | 0% | 3 studies (3/-) | 99.9 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.71 [0.45, 1.12] | | < 1 | | 0% | 1 study (1/-) | 92.9 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.54 [0.35, 0.83] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.71 [0.59, 0.85] | | < 1 | | 37% | 4 studies (4/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 1.93 [1.16, 3.20] | | > 1 | | 70% | 3 studies (3/-) | 99.4 % | some concern | not evaluable | moderate | non important | - |
| objective responses (ORR) (extension) | 2.80 [1.34, 5.83] | | > 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| STRAE (any grade) | 2.12 [1.63, 2.76] | | < 1 | | 0% | 4 studies (4/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 2.14 [1.60, 2.87] | | < 1 | | 0% | 4 studies (4/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 1.28 [0.58, 2.81] | | < 1 | | 84% | 4 studies (4/-) | 26.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 1.42 [0.87, 2.31] | | < 1 | | 78% | 4 studies (4/-) | 8.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.20 [0.44, 3.23] | | < 1 | | 0% | 3 studies (3/-) | 36.1 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 1.76 [0.82, 3.79] | | < 1 | | 81% | 4 studies (4/-) | 7.5 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 2.50 [0.95, 6.59] | | < 1 | | 78% | 4 studies (4/-) | 3.2 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Acute kidney injury TRAE (grade 3-4) | 4.32 [0.19, 97.73] | | < 1 | | 0% | 1 study (1/-) | 18.2 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.43 [0.12, 1.49] | | < 1 | | 86% | 4 studies (4/-) | 90.7 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 1.20 [0.46, 3.13] | | < 1 | | 0% | 3 studies (3/-) | 35.7 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.57 [0.10, 3.32] | | < 1 | | 0% | 4 studies (4/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.92 [0.37, 2.27] | | < 1 | | 0% | 4 studies (4/-) | 57.1 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.72 [0.65, 4.59] | | < 1 | | 0% | 4 studies (4/-) | 13.9 % | some concern | not evaluable | moderate | non important | - |
| Dizziness TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Dysgeusia TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.70 [0.78, 3.74] | | < 1 | | 2% | 4 studies (4/-) | 9.2 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.11 [0.07, 17.94] | | < 1 | | 0% | 2 studies (2/-) | 47.0 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 1.05 [0.06, 17.21] | | < 1 | | 0% | 1 study (1/-) | 48.6 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.05 [0.06, 17.21] | | < 1 | | 0% | 1 study (1/-) | 48.6 % | NA | not evaluable | | non important | - |
| Increased lacrimation (TRAE grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.68 [0.28, 1.64] | | < 1 | | 0% | 4 studies (4/-) | 80.3 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.22 [0.02, 2.28] | | < 1 | | 81% | 4 studies (4/-) | 89.6 % | some concern | not evaluable | moderate | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.52 [0.02, 15.84] | | < 1 | | 0% | 1 study (1/-) | 64.4 % | NA | not evaluable | | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.05 [0.02, 53.86] | | < 1 | | 0% | 1 study (1/-) | 49.0 % | NA | not evaluable | | non important | - |
| Pneumonia TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 2.53 [0.45, 14.15] | | < 1 | | 0% | 4 studies (4/-) | 14.7 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 5.69 [1.18, 27.31] | | < 1 | | 0% | 4 studies (4/-) | 1.5 % | some concern | not evaluable | moderate | non important | - |
| Sepsis TRAE (grade 3-4) | 2.12 [0.07, 64.42] | | < 1 | | 0% | 1 study (1/-) | 33.5 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 1.05 [0.06, 17.21] | | < 1 | | 0% | 1 study (1/-) | 48.6 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.52 [0.02, 15.84] | | < 1 | | 0% | 1 study (1/-) | 64.4 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 1.05 [0.14, 7.73] | | < 1 | | 0% | 1 study (1/-) | 48.0 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.45 [0.10, 1.97] | | < 1 | | 48% | 4 studies (4/-) | 85.6 % | some concern | not evaluable | moderate | non important | - |
